Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Murugan, Ravichandran N ^a   Ahn, Mija ^a   Lee, Woo Cheol ^a   Kim, Hye Yeon ^a   Song, Jung Hyun ^a   Cheong, Chaejoon ^a   Hwang, Eunha ^a   Seo, Ji Hyung ^a   Shin, Song Yub ^b   Choi, Sun Ho ^c,d   Park, Jung Eun ^d   Bang, Jeong Kyu ^a  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b Chosun University   (South Korea)

^c Research Laboratories   (South Korea)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; PL 100; PL 106; PL 42; PL 49; PL 55; PL 64; PL 74; PL 81; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; POLO LIKE KINASE INHIBITOR; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR RECOGNITION; STRUCTURE ACTIVITY RELATION;

CELL CYCLE PROTEINS; CRYSTALLOGRAPHY, X-RAY; PEPTIDES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892415831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080043     Document Type: Article

References (21)

1. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009. doi: 10.1038/nature06526. PubMed: 18075579.
2. Whitty A, Kumaravel G (2006) Between a rock and a hard place? Nat Chem Biol 2: 112-118. doi:10.1038/nchembio0306-112. PubMed: 16484997.
3. DeLano WL, Ultsch MH, de Vos AM, Wells JA (2000) Convergent solutions to binding at a protein-protein interface. Science 287: 1279-1283. doi:10.1126/science.287.5456.1279. PubMed: 10678837.
4. Atwell S, Ultsch M, de Vos AM, Wells JA (1997) Structural plasticity in a remodeled protein-protein interface. Science 278: 1125-1128. doi: 10.1126/science.278.5340.1125. PubMed: 9353194.
5. Keskin O, Gursoy A, Ma B, Nussinov R (2008) Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem Rev 108: 1225-1244. doi:10.1021/cr040409x. PubMed: 18355092.
6. Park JE, Soung NK, Johmura Y, Kang YH, Liao C et al. (2010) Polo-box domain: a versatile mediator of polo-like kinase function. Cell Mol Life Sci 67: 1957-1970. doi:10.1007/s00018-010-0279-9. PubMed: 20148280.
7. Murugan RN, Park JE, Kim EH, Shin SY, Cheong C et al. (2011) Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells 32: 209-220. doi:10.1007/s10059-011-0126-3. PubMed: 21809214.
8. Xu J, Shen C, Wang T, Quan J (2013) Structural basis for the inhibition of Polo-like kinase 1. Nat Struct Mol Biol 20: 1047-1053. doi:10.1038/nsmb.2623. PubMed: 23893132.
9. Kang YH, Park JE, Yu LR, Soung KK, Yun SM et al. (2006) Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol Cell 24: 409-422. doi:10.1016/j.molcel.2006. 10.016. PubMed: 17081991.
10. Yun SM, Moulaei T, Lim D, Bang JK, Park JE et al. (2009) Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 16: 876-882. doi: 10.1038/nsmb.1628. PubMed: 19597481.
11. Śledź P, Stubbs CJ, Lang S, Yang YQ, McKenzie GJ et al. (2011) From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1. Angew Chem Int Ed Engl 50: 4003-4006. doi:10.1002/anie.201008019. PubMed: 21472932.
12. Liu F, Park JE, Qian WJ, Lim D, Gräber M et al. (2011) Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol 7: 595-601. doi:10.1038/nchembio.614. PubMed: 21765407.
13. McInnes C, Estes K, Baxter M, Yang Z, Farag DB et al. (2012) Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther 11: 1683-1692. doi:10.1158/1535-7163.MCT-12-0006-T. PubMed: 22848093.
14. Liu F, Park JE, Qian WJ, Lim D, Scharow A et al. (2012) Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol 7: 805-810. doi:10.1021/cb200469a. PubMed: 22292814.
15. Liu F, Park JE, Qian WJ, Lim D, Scharow A et al. (2012) Peptoidpeptide hybrid ligands targeting the polo box domain of polo-like kinase 1. Chembiochem 13: 1291-1296. doi:10.1002/cbic.201200206. PubMed: 22570300.
16. Qian WJ, Park JE, Lee KS, Burke TR Jr (2012) Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). Bioorg Med Chem Lett 15: 7306-7308.
17. Śledź P, Lang S, Stubbs CJ, Abell C (2012) High-throughput interrogation of ligand binding mode using a fluorescence-based assay. Angew Chem Int Ed Engl 51: 7680-7683. doi:10.1002/anie.201202660. PubMed: 22730171.
18. Qian W, Park JE, Liu F, Lee KS, Burke TR Jr (2013) Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. Bioorg Med Chem 21: 3996-4003. doi:10.1016/j.bmc.2012.05.036. PubMed: 22743087.
19. DeLano WL (2002) The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA.
20. Kim YK, Arai MA, Arai T, Lamenzo JO, Dean EF III et al. (2004) Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. J Am Chem Soc 126: 14740-14745. doi:10.1021/ ja048170p. PubMed: 15535697.
21. Ueki H, Ellis TK, Martin CH, Boettiger TU, Bolene SB et al. (2003) Improved synthesis of proline-derived Ni(II) complexes of glycine: Versatile chiral equivalents of nucleophilic glycine for general asymmetric synthesis of α-amino acids. J Org Chem 68: 7105-7107.